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Abstract 
 
Chronic cancer pain is a serious complication of malignancy or its treatment. Currently, no 
comprehensive, universally accepted cancer pain classification system exists. Clarity in 
classification of common cancer pain syndromes would improve clinical assessment and 
management. Moreover, an evidence-based taxonomy would enhance cancer pain research 
efforts by providing consistent diagnostic criteria, ensuring comparability across clinical 
trials. As part of a collaborative effort between the Analgesic, Anesthetic, and Addiction 
Clinical Trial Translations Innovations Opportunities and Networks (ACTTION) and the 
American Pain Society (APS), the ACTTION-APS Pain Taxonomy (AAPT) initiative worked to 
develop the characteristics of an optimal diagnostic system.
59, 65
  Following the 
establishment of these characteristics, a working group consisting of clinicians and clinical 
and basic scientists with expertise in cancer and cancer-related pain was convened to 
generate core diagnostic criteria for an illustrative sample of 3 chronic pain syndromes 
associated with cancer (i.e., bone pain and pancreatic cancer pain as models of pain related 
to a tumor) or its treatment (i.e., chemotherapy-induced peripheral neuropathy). A 
systematic review and synthesis was conducted to provide evidence for the dimensions that 
comprise this cancer pain taxonomy. Future efforts will subject these diagnostic categories 
and criteria to systematic empirical evaluation of their feasibility, reliability and validity and 
extension to other cancer-related pain syndromes.   
Perspective 
The ACTTION-APS chronic cancer pain taxonomy provides an evidence-based classification 
for 3 prevalent syndromes, namely malignant bone pain, pancreatic cancer pain, and 
chemotherapy-induced peripheral neuropathy. This taxonomy provides consistent 
diagnostic criteria, common features, co-morbidities, consequences, and putative 
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mechanisms for these potentially serious cancer pain conditions that can be extended and 
applied with other cancer-related pain syndromes. 
Key words 
Cancer pain, taxonomy, bone pain, chemotherapy-induced peripheral neuropathy, 
pancreatic cancer 
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AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions 
 
Introduction 
 
One significant barrier to better understanding the growing dilemma of chronic 
cancer pain is the lack of consistent diagnostic criteria that can be used in research and 
clinical settings. A common taxonomy would provide a foundation for studies of the 
prevalence, as well as the consequences of these pain syndromes for people with cancer; 
present evidence for the significance of this problem; support the need for improvements in 
management; and increase research efforts.
153
  This standardized classification system 
would enhance research efforts by ensuring greater homogeneity in pain conditions across 
clinical trials and support the development of animal models to replicate these cancer pain 
conditions. Ultimately, valid and reliable diagnostic criteria would facilitate clinical 
assessment and management and potentially guide prognostic accuracy.
59, 65
 
  Current systems to classify cancer pain provide general clinical utility. Cancer pain is 
often organized by its intensity (e.g., mild, moderate or severe), its expected time course 
(e.g., acute versus chronic), its presumed underlying pathophysiology (e.g., nociceptive 
versus neuropathic), its location (e.g., head and neck pain), or its putative mechanisms (e.g., 
tumor-related, treatment-related, pain unrelated to tumor or treatment).
126
 Although these 
general categories are useful, more specific diagnostic criteria would allow more precise 
diagnosis with therapeutic implications and would enhance research efforts. 
 This lack of a unified taxonomy is not specific to cancer pain. Currently, there is an 
absence of evidence-based classification systems for most chronic pain conditions. 
65
 To 
meet this need, the Analgesic, Anesthetic, and Addiction Clinical Trial Translations 
Innovations Opportunities and Networks (ACTTION), a public-private partnership with the 
U.S. Food and Drug Administration and the American Pain Society (APS) collaborated to 
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develop the ACTTION-APS Pain Taxonomy (AAPT). The initiative worked to develop the 
characteristics of an ideal diagnostic system that would be biologically plausible, exhaustive, 
mutually exclusive, reliable, clinically useful, and simple through consensus conferences. The 
resulting diagnostic system includes 5 dimensions:  
1. Core diagnostic criteria 
2. Common features 
3. Common medical comorbidities 
4. Neurobiological, psychological, and functional consequences 
5. Putative neurobiological and psychosocial mechanisms, risk factors, and protective 
factors. 
65
 
 Following the establishment of these 5 dimensions, a working sub-group of clinical 
and basic scientists and clinicians with expertise in cancer pain was convened by the AAPT 
organizers. The aim of their effort was to apply the ideal framework of 5 dimensions 
developed during the original AAPT conference to cancer pain. The objectives included: (1) 
to identify chronic pain syndromes seen in oncology with high prevalence and significant 
impact and (2) to generate a classification system of diagnostic criteria for several of these 
syndromes based on these originally proposed 5 dimensions.   
Methods 
 
A working group of clinicians and clinical and basic scientists with expertise in cancer 
pain met during a consensus meeting held in July 2014. Group members from the United 
States and the United Kingdom were carefully selected based upon their contributions to 
the science and management of cancer pain, representing multiple disciplines (basic 
scientists, physicians, and nurses) with significant achievements in cancer-related 
epidemiology, research, and clinical care.    
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Prior to this meeting, a systematic review was conducted by two of the working 
group members (MM, MB) using the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) reporting system.
99
  PRISMA is an evidence-based minimum set of 
items for reporting systematic reviews and meta-analyses. The databases searched included 
the following: the Cumulative Index to Nursing and Allied Health Literature (CINAHL) from 
1981 to June 2014; the Cochrane Library of Systematic Reviews and the Cochrane Library of 
Controlled Trials from inception to June 2014; Database of Abstracts of Reviews of Effect 
from inception to April 2014; Embase Classic and Embase from 1947 to June 2014; Ovid 
MEDLINE® 1946 to June 2014; and OVID MEDLINE® In-Process and Other Non-Indexed 
Citations on June 11, 2014.  These databases were searched for review articles (including 
summary reports, systematic reviews, and meta-analyses), as well as observational and 
experimental studies published in English. Articles were excluded if they did not describe 
the clinical characteristics of chronic cancer pain, including those that described animal 
studies, or were studies of acute or breakthrough cancer pain. Data were extracted and 
summarised descriptively with respect to the 5 AAPT diagnostic dimensions: (1) core 
diagnostic criteria, (2) common features, (3) common medical co-morbidities, (4) 
neurobiological, psychosocial and functional consequences, (5) putative neurobiological and 
psychosocial mechanisms, risk factors, and protective factors. Figure 1 illustrates the 
process employed in this systematic review. Key words included cancer pain, malignancy, 
chemotherapy, surgery, radiotherapy and neuropathy.  
Bone pain, post-mastectomy pain, head and neck pain, neuropathic pain (disease 
related), and chemotherapy-induced peripheral neuropathy were most frequently 
referenced. These results were correlated with prevalence data of pain reported by tumor 
site, that generally demonstrate higher rates of pain reports in people with pancreatic, lung, 
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genitourinary, breast and prostate cancers.
20
 The expert panel considered these and other 
pain syndromes aiming to initiate the process of taxonomy development with 3 syndromes 
before extending to the full range of cancer-related pain syndromes at a later time. The 
challenge in narrowing the selection to 3 syndromes was to achieve a balance between the 
most prevalent cancer pain syndromes versus areas that have received the most study and 
thus have the largest body of evidence. Ultimately guiding the selection was the aim to 
identify those syndromes with clinical or research utility (i.e., the painful conditions that are 
most homogeneous in terms of mechanism or presentation and offer the most relevant 
targets for further research).  
Through working group discussion, debate and verbal consensus, 3 chronic pain 
syndromes seen as a result of cancer (i.e., bone pain and pancreatic cancer pain as a model 
of pain related to the tumor) or its treatment (chemotherapy-induced peripheral 
neuropathy) were unanimously selected. Head and neck pain was omitted because the 
source of this pain may be multifactorial (e.g., tumor, treatment related, or both) and 
diverse in relationship to specific anatomic location. Similarly, the working group agreed 
that disease-related neuropathic pain was too broad. While post-surgical pain syndromes, 
including post-mastectomy pain, were initially included, this group of pain conditions was 
omitted from the cancer-related pain taxonomy to avoid overlap with a broader discussion 
of post-surgical pain syndromes being conducted concurrently by a separate working group 
classifying neuropathic pain.  
Then the cancer pain working group generated a classification for these syndromes 
based upon the AAPT multidimensional framework. This work was conducted during the 
consensus meeting and later refined through on-line discussion. To ensure that the 
references were timely, the entire literature review was updated as of January 2015. The 
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manuscript reporting these findings was written by several members (JAP, MM, MB) and 
reviewed, edited and approved by all members of the working group.  
Results 
 Based on this qualitative review and after extensive discussion, the diagnostic 
criteria for 3 representative chronic cancer-related pain syndromes were developed 
collectively by the working group, including cancer-induced bone pain (CIBP), chemotherapy 
induced peripheral neuropathy (CIPN), and pancreatic cancer pain (PCP).  
Cancer-Induced Bone Pain 
It is estimated that 50-95% of all patients who die from cancer have bone 
involvement.
48, 132
 The most common cancers to originate in the bone are osteosarcomas.
84
 
Cancers that frequently metastasize to bone include prostate, breast, lung, and myeloma.
6, 7, 
14, 29, 38, 42, 47, 50, 52, 75, 87, 94, 106, 136
  Of those with bone metastases, approximately 85% 
experience pain, with resultant immobility and reduced quality of life.
54
 CIBP is a specific 
pain state with overlapping but distinct features of both acute nociceptive, inflammatory, 
and neuropathic pain processes.
61
  
Dimension 1. Core diagnostic criteria of CIBP 
 
The AAPT core diagnostic criteria for CIBP are summarized in Table 1. The history 
must include a cancer diagnosis and imaging evidence of bone disease consistent with 
primary or metastatic cancer. 
Dimension 2. Common features of CIBP 
The cardinal feature of CIBP is a mixture of continuous background pain (usually 
described as annoying, dull, gnawing, aching, and/or nagging)  punctuated by evoked or 
spontaneous pain (often described as electric or shock-like) in one or more locations 
generally consistent with the given known distribution of bone lesions, associated with 
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weight bearing or movement or can occur spontaneously.
14, 22, 40, 43, 49, 61, 63, 72, 73, 85, 88, 92, 95, 113, 
123, 125, 130, 132, 133, 140
  Generalised bone pain can occur due to the presence of multiple bone 
lesions or resultant expansion of bone marrow from bone metastases.
27, 61
  The distribution 
of the pain can be localised, radicular, or both.
73
 
Typical sites of CIBP include the vertebrae (lower thoracic spine and lumbar regions 
are most prevalent), pelvis, long bones, and ribs.
27, 49
  Bone lesions on the skull can result in 
headache pain due to calvarial, maxillary, or medullary lesions, as well as cranial nerve 
palsies such as mental nerve numbness or visual difficulties.
 25, 27
  Chest wall pain can occur 
as a result of bone lesions in the ribs.
27
  
As the disease and tumor mass progress, the background pain increases in intensity 
and interference 
61
 and is generally responsive to opioid analgesics, alone or in conjunction 
with nonsteroidal anti-inflammatory drugs.
10, 22, 63, 71, 79, 112
   Conversely, spontaneous pain 
(without specific eliciting stimuli) and evoked pain (i.e., in response to standing, weight 
bearing, movement, touch or other stimuli) associated with CIBP are difficult to treat from 
the onset due to their intermittent nature, which tends to be very rapid in onset, intense, 
and of short duration.
10, 22, 63, 71, 79, 112
  Terminology commonly used in the clinical setting to 
describe evoked or spontaneous pain include breakthrough pain, incident pain or a pain 
flare; however, definitions for these terms often lack precision and may overlap.  For 
example, breakthrough pain is defined as a transitory flare of pain in the setting of chronic 
pain managed with opioid drugs,
127
 yet the evoked pain seen in CIBP can occur during 
weight bearing without current opioid use. The International Association for the Study of 
Pain (IASP) Taxonomy, the principal resource for definitions related to chronic pain, does 
not currently address evoked, breakthrough, incident, flare or spontaneous pain.  
Dimension 3. Common medical comorbidities for CIBP 
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The primary comorbidity for CIBP is the presence of skeletal related events. These 
skeletal complications include pathological fractures of long bones, vertebrae, pelvis, rib, 
and other sites 
11, 24, 25, 27, 28, 48, 51, 154
 and in some cases spinal cord compression.
63, 73, 132
, 
56
 
Dimension 4. Neurobiological, psychosocial, and functional consequences of CIBP 
The consequences of CIBP can be serious because they affect biological, psychological, and 
functional aspects of the patient’s life. 
38, 73, 137
  Although some pathologic fractures produce 
limited pain, primary or metastatic bone lesions affecting the femur, pelvis, or spine are 
likely to cause significant pain during standing or ambulation, resulting in reduced 
mobility.
63
  Reduced quality of life and diminished activities of daily living are associated 
with CIBP.
41, 44, 48, 49, 91, 118, 132, 134, 160
 Functional impairment is strongly associated with 
evoked or breakthrough pain.
92, 113
 Fatigue is frequently reported in patients with metastatic 
bone disease and resultant pain.
133
    
Depression is common in people with painful bone metastases and has been found 
to be significantly associated with impaired quality of life.
134
  Additionally, the meaning of 
pain as a sign of advancing disease in those individuals with CIBP has been demonstrated to 
be correlated with increased pain intensity.
134
  Anxiety in men with advanced prostate 
cancer is associated with increase pain intensity and number of metastatic bone lesions.
86
 
These studies reveal that the consequences of CIBP are not unlike those seen in chronic 
non-cancer pain syndromes, including impaired function, mood, and quality of life.
60, 155
 
Dimension 5. Putative neurobiological and psychosocial mechanisms, risk factors, and 
protective factors for CIBP 
CIBP is a mixed mechanism condition that includes elements of acute nociceptive 
pain, inflammatory pain, and neuropathic pain.
58, 61, 70, 103, 125, 132
  Distinctive peripheral 
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modifications to bone and nervous tissues occur as well as neurobiological changes at the 
level of the spinal cord.
61, 70
   
Acute nociceptive pain occurs due to localised bone destruction, which leads to loss 
of structural integrity and a decrease in pH. Cancer cells do not destroy bone directly, but 
rather they express the receptor activator of nuclear factor k-B ligand (RANKL), which binds 
to its receptor, RANK. Activation of the RANKL/RANK pathway stimulates the production of 
bone destroying osteoclasts.
103
 Osteoclasts resorb bone by forming a highly acidic 
environment between the osteoclast and the bone. This stimulates the TRPV1 or ASIC3 
channels expressed by a significant population of nociceptors that ultimately leads to the 
perception of incident pain with movement and weight bearing activities.
61
 
Inflammatory pain develops when peripheral nerve endings in bone marrow and 
bone matrix are sensitized by localised inflammatory mediators stimulated by the cancer 
cells or their associated stromal cells. Locally released factors include bradykinin, 
endothelins, interleukin (IL)-6, granulocyte–macrophage colony-stimulating factor, nerve 
growth factor (NGF), proteases, and tumor necrosis factor (TNF)-a.
103
 This change is 
generally associated with steady background pain.
61
 
Neuropathic pain results from compression, distension, increase in sprouting, or 
denervation of nerve endings and/or axonal structures caused by expansion of the tumor. 
These changes lead to spontaneous pain and associated altered sensations.
61
 
Nociceptive and neuropathic mechanisms work in concert to produce a complex 
mixture of ongoing acute, inflammatory and neuropathic processes. These processes lead to 
a hyper-excitable state within the spinal cord, which itself is associated with amplification 
and modification of noxious and non-noxious peripheral stimuli.
61, 70, 156
   
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
  Chronic Cancer Pain 
 
14 
 
Interventions to protect against CIBP have been developed based upon current 
understanding of the underlying neurobiology. Bisphosphonates bind to bone, interfering 
with osteoclast function, later resulting in osteoclast apoptosis.
103
 Osteoprotegerin or 
denosumab, therapies that interfere with RANKL binding to RANK deplete activated 
osteoclasts, reduce signs of bone resorption, and diminish bone cancer pain.
146
 This is a 
rapidly evolving area of research and numerous studies are  underway to examine 
compounds that might block CIBP.
146
 Regarding putative psychosocial mechanisms 
associated with CIBP or other risk factors, little is currently understood and additional 
research is warranted.  
Chemotherapy-Induced Peripheral Neuropathy  
Chemotherapy induced peripheral neuropathy (CIPN) is a serious treatment induced 
toxicity that can limit function, impair quality of life, and in some cases, diminish the 
potential for cure when chemotherapy doses need to be reduced. 
9
  This condition is 
increasing in prevalence as greater numbers of neurotoxic agents are introduced and as 
patients live longer with the consequences of neuropathy. In a recent systematic review of 
31 studies with data from 4179 patients, CIPN prevalence was 68.1% (57.7–78.4) in the first 
month after chemotherapy, 60.0% (36.4–81.6) at 3 months and 30.0% (6.4–53.5) at 6 
months or later.
141
  
Dimension 1. Core diagnostic criteria of CIPN 
 
CIPN occurs in oncology patients when treatment involves a neurotoxic agent. A 
temporal relationship exists between the onset of symptoms and the starting, stopping, and 
duration of therapy.
34, 37, 46, 62, 78, 148
  Peripheral sensory and motor nerve damage or 
dysfunction are the putative mechanisms for CIPN.
36, 37, 62, 101, 121, 148, 151, 162
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CIPN poses a significant challenge for the patient and clinician in terms of diagnosis, 
management and associated reductions in function and quality of life, particularly in 
patients with coexisting conditions or disorders that involve the peripheral nervous system 
(e.g., diabetes, HIV).
2, 33, 68, 78, 80, 81, 104, 120, 121, 148, 151
  Table 2 lists the core diagnostic criteria 
for CIPN. 
Dimension 2. Common features of CIPN 
The cardinal feature of dose-limiting CIPN is a gradually-progressive distal 
symmetrical sensory neuropathy (stocking/glove distribution), which may be associated 
with diminished motor function. However, more often than not motor symptoms are absent 
until later stages of CIPN.
3, 13, 36, 37, 62, 78, 80, 101, 121, 148, 151, 162
 Neuropathy in the feet without 
involvement in the hands is common.  In addition to descriptors such as “tingling” or 
“burning”, patients often describe these sensory abnormalities with terms such as 
“discomfort” or “unpleasant”. Cramping, more common in the lower limbs, may be 
reported.
151
  
Clinical examination reveals sensory loss to one or more sensory modalities and/or 
evoked pain in a stocking and glove distribution. These findings include hypoesthesia (a 
bilateral increase in detection thresholds to tactile, vibration, or non-noxious warm or cool 
stimuli)
53, 57, 78
, or hypoalgesia (a bilateral increase in pain detection thresholds to blunt 
pressure or pinprick stimuli)
53, 57, 78
, or hyperalgesia (a bilateral decrease in pain detection 
threshold to noxious heat or cold stimuli.)
18, 53
  The anatomic distribution of these physical 
examination findings may not correspond exactly to the sensory symptoms.
2, 30, 46, 53, 78, 80, 109, 
115, 120, 148, 152, 158, 162
 
 Signs and symptoms of CIPN, including pain, commonly begin in the lower 
extremities followed by the upper extremities and progress proximally.
78
  However, not all 
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go on to experience neuropathy in the upper extremities. The temporal features of CIPN are 
rapid onset (hours or days) of sensory abnormalities following initiation of neurotoxic 
chemotherapy.
78, 101
  In the majority of cases, the onset of CIPN symptoms and signs is 
progressive; beginning with mild paraesthesias in the lower extremities, becoming 
progressively more intense, and advancing proximally with cumulative dose exposure.
78, 101
 
Some patients may experience a reduction in the intensity of symptoms between 
treatment cycles – sometimes referred to as a waxing and waning effect.
122
  In some cases, 
symptoms and signs of CIPN may continue or worsen after treatment has ended, a 
phenomenon known as ‘coasting’.
37, 78, 101
  Increasing evidence suggests that pre-existing 
sensory deficits (clinical or sub-clinical neuropathy) are associated with the onset of more 
extensive and severe CIPN symptoms and signs.
18, 53
  The prevalence of autonomic changes 
associated with CIPN is poorly understood, but can include serious complications such as 
falls related to orthostatic hypotension.
1
 
Agents most likely to result in CIPN include platinum based drugs (e.g., cisplatin, 
carboplatin, and oxaliplatin), vinca alkaloids (e.g., vincristine, vinblastine), taxanes (e.g., 
paclitaxel, docetaxel), bortezomib, thalidomide, lenalidomide, eribulin, and ixabepilone. The 
frequency and severity of CIPN is generally related to the specific drug, dose, schedule (e.g., 
more prevalent with weekly versus every 3 week dosing of paclitaxel), speed of 
administration, and duration of therapy.
111
  In the case of bortezomib, route of delivery 
affected the prevalence of CIPN. Peripheral neuropathy of any grade was significantly less 
common with subcutaneous bortezomib administration compared to intravenous 
delivery.
114
   
Sensations described by patients vary with the administered chemotherapeutic 
agent. In a recent prospective study that compared the experience of patients receiving 
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docetaxel versus oxaliplatin, tingling was the most common symptom experienced by both 
groups, yet pain and discomfort associated with cold was uniquely reported by those who 
received oxaliplatin.
157
 
Motor weakness, with a similar peripheral distribution to sensory alterations, can 
occur in CIPN, but overall is observed less frequently than sensory abnormalities.
62, 101, 141
 
However, patients frequently demonstrate a decrease in mechano-sensory function, as 
measured by a timed pegboard test or the time taken to button a shirt.
16, 17, 128
  Importantly, 
impaired proprioception is reported by many patients with CIPN, described as feeling 
unbalanced, particularly in the absence of visual cues when walking or standing (e.g., in dark 
settings, when closing one’s eyes in the shower).
78, 116
  Clinical examination may reveal a 
positive Romberg sign and generalised ataxia in more severe cases.
124
  Symmetrical loss of 
deep tendon reflexes (Achilles or brachioradialis) is a sign of more advanced CIPN.
78
 
Dimension 3. Common medical comorbidities of CIPN 
People at greatest risk for CIPN are believed to include those with comorbid 
conditions known to contribute to neuropathy, including diabetes, obesity, and HIV, .
81, 128, 
141
 Pharmacogenetic profiling of genetic polymorphisms has been conducted to identify 
susceptibility to CIPN based on genetic polymorphisms. For example, polymorphisms in the 
CYP2C8 and CYP3A5 genes that encode for paclitaxel metabolizing enzymes were found to 
be associated with CIPN.
31, 82
  Even though pharmacogenetic profiling may one day identify 
patients at greater risk for severe CIPN, the data so far are insufficient to draw any definitive 
conclusions. 
Dimension 4. Neurobiological, psychosocial, and functional consequences of CIPN 
Terminal axonal degeneration and axonal microtubule disruption are the most 
common pathophysiologic consequences observed in CIPN.
78
  Psychosocial consequences of 
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CIPN include depression, anxiety, impaired sleep and other mood changes.
69, 83, 151, 157
  The 
functional outcomes of CIPN range from mild symptoms which do not interfere with 
activities of daily living (ADL) to moderate and severe dose-limiting sensory and motor 
alterations that interfere with ADLs .
32, 34-37, 131
   The need to limit doses of chemotherapy 
due to CIPN can lead to shortened survival. In the most severe cases sensory and motor 
alterations are disabling, resulting in paralysis, complete loss of function, or both.
101, 104, 147
 
Dimension 5. Putative neurobiological and psychosocial mechanisms, risk factors, and 
protective factors for CIPN 
The underlying pathophysiologic mechanism(s) that lead to the development of CIPN 
are not completely understood. Nevertheless, the similarity in the pattern and spectrum of 
clinical symptoms and signs of CIPN caused by different chemotherapeutic agents is 
apparent. Common underlying mechanisms purported to be involved in the development of 
CIPN are: 
5, 12, 23, 62, 77, 119, 122, 152, 161, 162
 
• Disruption of axoplasmic microtubule-mediated transport causing distal axonopathy, 
a known cellular effect of many chemotherapy agents 
• Distal axonal degeneration 
• Direct damage to sensory nerve cell bodies of the dorsal root ganglia 
• Mitochondrial dysfunction  
• Activation of protein kinases and extracellular kinases (associated with cisplatin- 
induced CIPN) 
• Oxaliplatin is associated with actual nerve cell death and decreased epidermal nerve 
fiber density with each cycle, as well as decreased conduction velocity and amplitude  
• Alteration of gene expression thought to be involved in pain mediation in spinal cord 
dorsal horn (associated with vincristine exposure) 
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• Decrease in the density of grey matter after one month in women with breast cancer 
experiencing CIPN 
• Central sensitization as a consequence of long-term peripheral nerve injury 
A recent systematic review explored risk factors for CIPN and found the following 
elements: baseline neuropathy, smoking, abnormal creatinine clearance and distinct 
sensory changes during chemotherapy treatment, including cold allodynia and cold 
hyperalgesia.
141
  Sensory changes during chemotherapy treatment, including increased pain 
and neuronal hyperexcitability, are also predictors of CIPN.
141
 A prospective study of 
patients receiving oxaliplatin and followed for 1 year found that those patients with 
elevated heat detection thresholds (higher temperature levels were needed to perceive 
heat) before receiving chemotherapy were more likely to experience intense CIPN.
128
  
Few protective factors for CIPN have been identified. A recent investigation 
employed large Medicare claims data and found that a history of autoimmune disease was 
associated with reduced risk of CIPN.
81
 Regarding prevention of CIPN, a recent clinical 
practice guideline from the American Society of Clinical Oncology reviewed existing 
evidence. After extensive analysis, the authors were unable to recommend any agents to 
prevent this syndrome due to the lack of high quality evidence.
80
 
Pancreatic cancer pain 
The estimated incidence of pancreatic cancer for 2016 is more than 53,000 in the 
U.S., with approximately 42,000 dying from this disease.
144
  Risk factors for pancreatic 
cancer include family history, obesity, smoking, and chronic pancreatitis.
89, 145, 149
  Upper 
abdominal pain is a common presenting symptom of pancreatic cancer. The prevalence of 
pain associated with pancreatic cancer ranges from 72-100%.
15
 
Dimension 1. Core diagnostic criteria of PCP 
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Pancreatic cancer pain occurs in the presence of a diagnosis of pancreatic cancer 
confirmed by imaging evidence of an epigastric mass and/or biopsy that establishes the 
diagnosis.  Table 3 presents the core diagnostic criteria. 
Dimension 2. Common features of PCP 
The cardinal features of pancreatic cancer pain are upper abdominal pain with 
frequent extension to the back, either to the low back or the region between the scapulae 
spreading laterally, and unexplained weight loss.
143
  Less frequently PCP is diffuse within the 
abdomen or referred to the lower abdominal quadrants.
26, 90
  The pain is often described as 
dull, aching, gnawing or spasmodic 
26, 143
 and the intensity can fluctuate throughout the day 
with position (e.g., exacerbated by supine positioning) and food ingestion.
143
  Pain intensity 
usually increases with disease severity. However, because this cancer is often diagnosed 
late, 20-30% of patients report moderate to severe pain at diagnosis.
26
 The back pain 
associated with PCP may be worse when the patient is supine and eased by sitting 
forward.
26, 90, 143
 
Dimension 3. Common medical comorbidities of PCP 
Jaundice and dark urine can be a presenting symptom in cancers of the pancreatic 
head.
143
 Unexplained weight loss, anorexia, diabetes, and other sequelae of pancreatic 
cancer or its treatment are common.
15, 90, 143
  To date, few medical comorbidities of 
pancreatic cancer pain have been identified. 
Dimension 4. Neurobiological, psychosocial, and functional consequences of PCP 
Because pancreatic cancer is highly associated with pain, it is difficult to discern 
whether other symptoms are related to the cancer or pain. Several studies have 
documented a very high prevalence of depressed mood in those patients with pancreatic 
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cancer, higher than other cancers with similar prognoses.
8, 26, 45
  Symptom burden in general 
is high in this population, notably including disturbed sleep and fatigue
90
 as well as nausea 
and vomiting associated with obstruction or delayed gastric emptying.
15
 
Dimension 5. Putative neurobiological and psychosocial mechanisms, risk factors, and 
protective factors for PCP 
Pain occurs in 90% of patients with cancer of the head of the pancreas and is much 
less common in cancer of pancreatic body or tail.
26, 64, 143
  Back pain often indicates that 
retroperitoneal or celiac plexus infiltration has occurred.
143
 Putative mechanisms include 
compression or infiltration (perineural invasion) of splanchnic nerves in the celiac plexus by 
direct local tumour expansion,
8, 19, 117, 143
  as well as compression of surrounding tissues and 
organs. Celiac plexus block has been found to be effective in relieving PCP.
4, 107, 135
 It is 
unclear if relief signifies extension of tumor into the plexus, or interruption of visceral 
afferent neurons that are also found in the plexus. No other risk factors or protective factors 
for PCP could be identified. 
Discussion 
Cancer-related pain remains a complex, multidimensional phenomenon. The 
exercise of developing a standardized, rigorous, valid taxonomy for just 3 common cancer 
pain syndromes revealed the limitations in our existing nomenclature. Current studies 
attempting to characterize and establish prevalence rates for specific cancer pain 
syndromes are hampered by the absence of explicit definitions. A clear example is the large, 
prospective study by Ventzel and colleagues comparing neuropathy characteristics in 
patients receiving oxaliplatin versus docetaxel.
157
  Although the prevalence of pain in the 
hands and feet was approximately equal between the 2 groups, on further analysis, a 
significant percentage of those treated with docetaxel reported less burning and numbness, 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
  Chronic Cancer Pain 
 
22 
 
suggesting the pain was not consistent with CIPN. The investigators postulated this 
difference may be related to the use of adjuvant endocrine therapies, such as the 
aromatase inhibitors, often prescribed for those who have received docetaxel. These 
endocrine therapies are known to cause arthralgias, myalgias and carpal tunnel 
syndrome.
110, 142
  The investigators used a variety of questionnaires to determine these 
differences, yet not all clinicians or researchers will be able to employ such an extensive 
battery of measures. It is our hope that the core diagnostic criteria will help future 
investigators to not only better characterize cancer pain syndromes, as was done in this 
study, but to differentiate them from related phenomenon to avoid inaccurate 
interpretations.
100
 
 The consequences of cancer pain can be significant, including deleterious effects on 
function, mood, sleep, fatigue, and ultimately, quality of life. 
60, 155
 Additionally, increased 
intensity of cancer pain is associated with heightened suffering in those at end of life.
159
 
Finally, studies support the association between pain and reduced survival, demanding 
more urgent attention to this symptom. 
76, 129
 More research is warranted to discern the 
neurobiological, psychological, and functional consequences of each of these and other 
cancer pain syndromes.  
Another area that demands additional study is the determination of the mechanisms 
of cancer pain. While important work has begun in the area of CIBP, 
39, 102, 103, 105
 CIPN,
66, 74, 
97, 98
 and PCP, 
55, 93
 additional research is needed to elucidate the neurobiological factors 
responsible for cancer pain. An exciting line of investigation is the interactions among the 
cancer microenvironment, the primary afferent nociceptor, and the immune system.
138, 139
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An additional area of clarification relates to risk factors and protective determinants 
for cancer pain. Early research exploring cancer pain focused on clinical or biological factors, 
such cancer diagnosis, stage of disease, or treatment. In recent important work, Miaskowski 
and colleagues found that cancer patients with the highest symptom burden were 
significantly younger, more likely to be female and non-white, had lower levels of social 
support, lower socioeconomic status, poorer functional status, and a higher level of 
comorbidity.
108
  In a large study of people with breast cancer, colorectal cancer or prostate 
cancer, Lewis et al. found that factors associated with more severe CIPN included colon 
versus other cancers, the duration and type of therapy, poor socioeconomic status and 
black race. 
96
  Factors influencing cancer pain must be expanded in future studies, including 
psychosocial factors
60
 and overlapping chronic pain conditions and comorbidities.
100
 
Additionally, identification of genetic polymorphisms might allow for the identification of 
those at risk for these painful syndromes, as well as direct prevention and treatment 
innovations.  
Finally, an emerging area of research that requires further investigation is the 
development of phenotypic profiles of cancer pain syndromes based on symptoms and 
clinical signs. Recent studies in non-cancer chronic pain syndromes (such as diabetic 
peripheral neuropathy) suggest that stratification of patients into homogeneous groups 
based on symptom profiles may be advantageous for analgesic drug trials and ultimately 
lead to a more targeted approach to cancer pain management.
67, 150
 
This proposed taxonomy presents early work in developing a classification system for 
cancer related pain conditions. Current classification systems focusing on duration (acute 
versus chronic) or presumed etiology (related to the cancer, related to treatment, or 
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unrelated) do not provide the specificity needed to clearly define distinct cancer pain 
syndromes. There were numerous challenges in the development process, notably 
limitations in existing research related to cancer pain. Studies are often hampered by a wide 
array of weaknesses, including heterogeneous populations, small sample sizes, dissimilar 
assessment tools and techniques, and inadequate duration of investigations. Although the 
working group strove to identify diagnostic criteria that were absolutely necessary to 
describe each painful syndrome, once these criteria are applied more broadly, controversy 
will arise and modification will likely be indicated. Future work will now be required to 
validate this proposed taxonomy in populations of people with cancer and determine the 
feasibility of its use in both clinical and research settings. Investigators studying these 3 
syndromes should incorporate the core diagnostic criteria when employing research 
methods. Clinicians may find the use of the criteria of benefit when considering the 
differential diagnosis of complex cancer pain syndromes. This current undertaking classified 
just 3 syndromes; much additional work is needed to characterize the many other painful 
syndromes that occur in those individuals diagnosed with cancer.   
Conclusions 
 Three cancer pain syndromes, 2 related to cancer, and one related to a common 
cancer treatment, were classified using the AAPT multidimensional chronic pain taxonomy. 
Future work will demonstrate the validity and reliability of these proposed diagnostic 
criteria. 
21
 As our understanding of these cancer pain conditions matures, it is expected that 
the taxonomy will expand and evolve. It is the hope of this working group that classification 
of these cancer pain syndromes will ultimately strengthen clinical, scientific and educational 
efforts around cancer pain. Transforming our understanding of cancer pain is urgently 
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needed to improve its management as well as improve patients’ relief and survivors’ quality 
of life.   
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
  Chronic Cancer Pain 
 
26 
 
References 
 
 
1. Adams SC, Schondorf R, Benoit J, Kilgour RD. Impact of cancer and chemotherapy on 
autonomic nervous system function and cardiovascular reactivity in young adults with 
cancer: a case-controlled feasibility study. BMC Cancer  15:414, 2015 
2. Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou 
AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, 
Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, 
Fabbri S, Valsecchi MG, Cavaletti G, Group CI-P. Physician-assessed and patient-reported 
outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of 
the same coin. Ann Oncol 25:257-264, 2014 
3. Andersen KG, Jensen MB, Kehlet H, Gartner R, Eckhoff L, Kroman N. Persistent pain, sensory 
disturbances and functional impairment after adjuvant chemotherapy for breast cancer: 
cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and 
cyclophosphamide. Acta Oncol  51:1036-1044, 2012 
4. Arcidiacono Paolo G, Calori G, Carrara S, McNicol Ewan D, Testoni Pier A: Celiac plexus block 
for pancreatic cancer pain in adults. Cochrane Database of Systematic Reviews. 2011 
5. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral 
neurotoxicity (CIPN): an update. Crit Rev Oncol Hemat 82:51-77, 2012 
6. Bae HM, Lee SH, Kim TM, Kim DW, Yang SC, Wu HG, Kim YW, Heo DS. Prognostic factors for 
non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung cancer  
77:572-577, 2012 
7. Bagi CM. Skeletal implications of prostate cancer.J Musculoskelet Neuronal Interact 3:112-
117, 2003 
8. Bapat AA, Hostetter G, Von Hoff DD, Han H. Perineural invasion and associated pain in 
pancreatic cancer. Nat Rev Cancer 11:695-707, 2011 
9. Bhatnagar B, Gilmore S, Goloubeva O, Pelser C, Medeiros M, Chumsri S, Tkaczuk K, Edelman 
M, Bao T. Chemotherapy dose reduction due to chemotherapy induced peripheral 
neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or 
adjuvant settings: a single-center experience. Springerplus. 3:366, 2014 
10. Bianchi R, Gilardini A, Rodriguez-Menendez V, Oggioni N, Canta A, Colombo T, De Michele G, 
Martone S, Sfacteria A, Piedemonte G, Grasso G, Beccaglia P, Ghezzi P, D'Incalci M, Lauria G, 
Cavaletti G. Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin 
without affecting tumour growth. Eur J Cancer  43:710-717, 2007 
11. Bickels J, Dadia S, Lidar Z. Surgical management of metastatic bone disease. J  Bone Joint 
Surg 91:1503-1516, 2009 
12. Bilinska M, Usnarska-Zubkiewicz L, Pokryszko-Dragan A. Bortezomib-induced painful 
neuropathy in patients with multiple myeloma. Wspolczesna Onkologia  17:421-426, 2013 
13. Binda D, Cavaletti G. Chemotherapy induced peripheral neuropathy outcome measures 
standardisation (CI-PERINOMS) study. J Peripher Nerv Syst 16:S12, 2011 
14. Boland E, Eiser C, Ezaydi Y, Greenfield DM, Ahmedzai SH, Snowden JA. Living with advanced 
but stable multiple myeloma: A study of the symptom burden and cumulative effects of 
disease and intensive (hematopoietic stem cell transplant-based) treatment on health-
related quality of life. J Pain Symptom Manage 46:671-680, 2013 
15. Bond-Smith G, Banga N, Hammond TM, Imber CJ. Pancreatic adenocarcinoma. BMJ  
344:e2476, 2012 
16. Boyette-Davis JA, Cata JP, Driver LC, Novy DM, Bruel BM, Mooring DL, Wendelschafer-Crabb 
G, Kennedy WR, Dougherty PM. Persistent chemoneuropathy in patients receiving the plant 
alkaloids paclitaxel and vincristine. Cancer Chemother Pharmacol 71:619-626, 2013 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
  Chronic Cancer Pain 
 
27 
 
17. Boyette-Davis JA, Cata JP, Zhang H, Driver LC, Wendelschafer-Crabb G, Kennedy WR, 
Dougherty PM. Follow-up psychophysical studies in bortezomib-related chemoneuropathy 
patients.J Pain 12:1017-1024, 2011 
18. Boyette-Davis JA, Eng C, Wang XS, Cleeland CS, Wendelschafer-Crabb G, Kennedy WR, 
Simone DA, Zhang H, Dougherty PM. Subclinical peripheral neuropathy is a common finding 
in colorectal cancer patients prior to chemotherapy. Clin Cancer Res 18:3180-3187, 2012 
19. Brant JM. Cancer-related neuropathic pain. Nurse Pract Forum  9:154-162, 1998 
20. Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, Cohen R, Dow L. Cancer-
related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann 
Oncol  20:1420-1433, 2009 
21. Bruehl S, Ohrbach R, Sharma S, Widerstrom-Noga E, Dworkin RH, Fillingim RB, Turk DC. 
Approaches to Demonstrating the Reliability and Validity of Core Diagnostic Criteria for 
Chronic Pain. J Pain  17:T118-131, 2016 
22. Buga S, Sarria JE. The management of pain in metastatic bone disease. Cancer Control  
19:154-166, 2012 
23. Burakgazi AZ, Messersmith W, Vaidya D, Hauer P, Hoke A, Polydefkis M. Longitudinal 
assessment of oxaliplatin-induced neuropathy. Neurology  77:980-986, 2011 
24. Callstrom MR, Charboneau JW, Goetz MP, Rubin J, Atwell TD, Farrell MA, Welch TJ, Maus TP. 
Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a 
difficult problem. Skeletal Radiol  35:1-15, 2006 
25. Caraceni A. Evaluation and assessment of cancer pain and cancer pain treatment. Acta  
Anaesthesiol Scand 45:1067-1075, 2001 
26. Caraceni A, Portenoy RK. Pain management in patients with pancreatic carcinoma. Cancer 
78:639-653, 1996 
27. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and 
syndromes. Pain  82:263-274, 1999 
28. Caraceni A, Weinstein SM. Classification of cancer pain syndromes. Oncology (Williston Park, 
N.Y.). 15:1627-1640, 1642, 2001 
29. Carla R, Fabio T, Gloria B, Ernesto M. Prevention and treatment of bone metastases in breast 
cancer. J Clin Med  2:151-175, 2013 
30. Cata JP, Weng H, Burton AW, Villareal H, Giralt S, Dougherty PM. Quantitative sensory 
findings in patients with bortezomib-induced pain. J Pain 8:296-306, 2007 
31. Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the 
era of pharmacogenomics. Lancet Oncol  12:1151-1161, 2011 
32. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Parma G, Lissoni A, Fei F, 
Cundari S, Zanna C. Grading of chemotherapy-induced peripheral neurotoxicity using the 
Total Neuropathy Scale. Neurology  61:1297-1300, 2003 
33. Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, 
Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla 
Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, 
Kerrigan S, Schenone A, Fabbri S, Valsecchi MG. The chemotherapy-induced peripheral 
neuropathy outcome measures standardization study: from consensus to the first validity 
and reliability findings.  Ann Oncol 24:454-462, 2013 
34. Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, Cortinovis D, Bidoli P. 
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the 
currently available tools. Eur J Cancer 46:479-494, 2010 
35. Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, Zara G, Plasmati R, Pastorelli F, 
Caraceni A, Pace A, Manicone M, Lissoni A, Colombo N, Bianchi G, Zanna C. The Total 
Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced 
peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity 
Scale. J Peripher Nerv Syst 12:210-215, 2007 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
  Chronic Cancer Pain 
 
28 
 
36. Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple 
myeloma: a review of recent studies. Leuk Lymphoma 51:1178-1187, 2010 
37. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 
6:657-666, 2010 
38. Cetin K, Christiansen CF, Jacobsen JB, Norgaard M, Sorensen HT. Bone metastasis, skeletal-
related events, and mortality in lung cancer patients: A Danish population-based cohort 
study. Lung cancer 247-254, 2014 
39. Chartier SR, Thompson ML, Longo G, Fealk MN, Majuta LA, Mantyh PW. Exuberant sprouting 
of sensory and sympathetic nerve fibers in nonhealed bone fractures and the generation and 
maintenance of chronic skeletal pain. Pain  155:2323-2336, 2014 
40. Chen E, Khan L, Zhang L, Nguyen J, Cramarossa G, Tsao M, Danjoux C, Barnes E, Sahgal A, 
Holden L, Jon F, Dennis K, Culleton S, Chow E. Symptom clusters in patients with bone 
metastases - A reanalysis comparing different statistical methods. Support Care Cancer 
20:2811-2820, 2012 
41. Cheng EY. Prospective quality of life research in bony metastatic disease. Clin Orthop Relat 
Res 415S:S289-297, 2003 
42. Chow E, Doyle M, Li K, Bradley N, Harris K, Hruby G, Sinclair E, Barnes EA, Danjoux C. Mild, 
moderate, or severe pain categorized by patients with cancer with bone metastases.  J 
Palliat Med 9:850-854, 2006 
43. Chow E, Fan G, Hadi S, Filipczak L. Symptom clusters in cancer patients with bone 
metastases. Support Care Cancer 15:1035-1043, 2007 
44. Chow E, Hruby G, Davis L, Holden L, Schueller T, Wong R, Hayter C, Szumacher E, Loblaw A, 
Danjoux C. Quality of life after local external beam radiation therapy for symptomatic bone 
metastases: a prospective evaluation. Support Cancer Ther  1:179-184, 2004 
45. Clark KL, Loscalzo M, Trask PC, Zabora J, Philip EJ. Psychological distress in patients with 
pancreatic cancer--an understudied group. Psychooncology  19:1313-1320, 2010 
46. Cleeland CS, Farrar JT, Hausheer FH. Assessment of cancer-related neuropathy and 
neuropathic pain. Oncologist  15 Suppl 2:13-18, 2010 
47. Clemons M, Dranitsaris G, Cole D, Gainford MC. Too much, too little, too late to start again? 
Assessing the efficacy of bisphosphonates in patients with bone metastases from breast 
cancer. Oncologist  11:227-233, 2006 
48. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment 
strategies. Cancer Treat Rev  27:165-176, 2001 
49. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin 
Cancer Res 12:6243s-6249s, 2006 
50. Conti G, La Torre G, Cicalese V, Micheletti G, Ludovico MG, Vestita GD, Cottonaro G, Introini 
C, Cecchi M. Prostate cancer metastases to bone: observational study for the evaluation of 
clinical presentation, course and treatment patterns. Presentation of the METAURO protocol 
and of patient baseline features. Arch Ital Urol Androl  80:59-64, 2008 
51. Cook RJ, Major P. Methodology for treatment evaluation in patients with cancer metastatic 
to bone. J Natl Cancer Inst 93:534-538, 2001 
52. Coombes RC, Dady P, Parsons C. Assessment of response of bone metastases to systemic 
treatment in patients with breast cancer. Cancer  52:610-614, 1983 
53. de Carvalho Barbosa M, Kosturakis AK, Eng C, Wendelschafer-Crabb G, Kennedy WR, Simone 
DA, Wang XS, Cleeland CS, Dougherty PM. A Quantitative Sensory Analysis of Peripheral 
Neuropathy in Colorectal Cancer and Its Exacerbation by Oxaliplatin Chemotherapy. Cancer 
Res 5955-5962, 2014 
54. Delaney A, Fleetwood-Walker SM, Colvin LA, Fallon M. Translational medicine: cancer pain 
mechanisms and management. British J Anesth 101:87-94, 2008 
55. Demir IE, Friess H, Ceyhan GO. Neural plasticity in pancreatitis and pancreatic cancer. Nat 
Rev Gastroenterol Hepatol 12:649-659, 2015 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
  Chronic Cancer Pain 
 
29 
 
56. Donovan PJ, Achong N, Griffin K, Galligan J, Pretorius CJ, McLeod DS. PTHrP-mediated 
hypercalcemia: causes and survival in 138 patients. J Clin Endocrinol Metab  100:2024-2029, 
2015 
57. Dougherty PM, Cata JP, Burton AW, Vu K, Weng HR. Dysfunction in multiple primary afferent 
fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-
induced pain. J Pain Symptom Manage 33:166-179, 2007 
58. Dubey A, Koul R. Bone metastasis -- an overview. Internet Journal of Pain, Symptom Control 
& Palliative Care. 8:6p, 2010 
59. Dworkin RH, Bruehl S, Fillingim RB, Loeser JD, Terman GW, Turk DC. Multidimensional 
Diagnostic Criteria for Chronic Pain: Introduction to the ACTTION-American Pain Society Pain 
Taxonomy (AAPT). J Pain 17:T1-9, 2016 
60. Edwards RR, Dworkin RH, Sullivan MD, Turk DC, Wasan AD. The Role of Psychosocial 
Processes in the Development and Maintenance of Chronic Pain. J Pain  17:T70-92, 2016 
61. Falk S, Dickenson AH. Pain and nociception: mechanisms of cancer-induced bone pain. J Clin 
Oncol 32:1647-1654, 2014 
62. Farquhar-Smith P. Chemotherapy-induced neuropathic pain. Curr Opin Support Palliat Care 
5:1-7, 2011 
63. Farrell C. Bone metastases: assessment, management and treatment options. Br J Nurs 
22:S4, S6, S8-11, 2013 
64. Fasanella KE, Davis B, Lyons J, Chen Z, Lee KK, Slivka A, Whitcomb DC. Pain in Chronic 
Pancreatitis and Pancreatic Cancer. Gastroenterol Clin North Am 36:335-364, 2007 
65. Fillingim RB, Bruehl S, Dworkin RH, Dworkin SF, Loeser JD, Turk DC, Widerstrom-Noga E, 
Arnold L, Bennett R, Edwards RR, Freeman R, Gewandter J, Hertz S, Hochberg M, Krane E, 
Mantyh PW, Markman J, Neogi T, Ohrbach R, Paice JA, Porreca F, Rappaport BA, Smith SM, 
Smith TJ, Sullivan MD, Verne GN, Wasan AD, Wesselmann U. The ACTTION-American Pain 
Society Pain Taxonomy (AAPT): an evidence-based and multidimensional approach to 
classifying chronic pain conditions. J Pain 15:241-249, 2014 
66. Flatters SJ. The contribution of mitochondria to sensory processing and pain. Prog Mol Biol 
Transl Sci  131:119-146, 2015 
67. Freeman R, Baron R, Bouhassira D, Cabrera J, Emir B. Sensory profiles of patients with 
neuropathic pain based on the neuropathic pain symptoms and signs. Pain  155:367-376, 
2014 
68. Geber C, Breimhorst M, Burbach B, Egenolf C, Baier B, Fechir M, Koerber J, Treede RD, Vogt 
T, Birklein F. Pain in chemotherapy-induced neuropathy--more than neuropathic? Pain  
154:2877-2887, 2013 
69. Golan-Vered Y, Pud D. Chemotherapy-induced neuropathic pain and its relation to cluster 
symptoms in breast cancer patients treated with paclitaxel. Pain Pract  13:46-52, 2013 
70. Gordon-Williams RM, Dickenson AH. Central neuronal mechanisms in cancer-induced bone 
pain. Curr Opin Support Palliat Care 1:6-10, 2007 
71. Gough N, Miah AB, Linch M. Nonsurgical oncological management of cancer pain. Curr Opin 
Support Palliat Care 8:102-111, 2014 
72. Gralow J, Tripathy D. Managing metastatic bone pain: the role of bisphosphonates.  J Pain 
Symptom Manage 33:462-472, 2007 
73. Grant R, Papadopoulos SM, Greenberg HS. Metastatic epidural spinal cord compression. 
Neurol Clinics  9:825-841, 1991 
74. Griffiths LA, Flatters SJ. Pharmacological Modulation of the Mitochondrial Electron Transport 
Chain in Paclitaxel-Induced Painful Peripheral Neuropathy. J Pain 16:981-994, 2015 
75. Hage WD, Aboulafia AJ, Aboulafia DM. Incidence, location, and diagnostic evaluation of 
metastatic bone disease. Orthop Clin North Am  31:515-528, vii, 2000 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
  Chronic Cancer Pain 
 
30 
 
76. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ. Pain predicts 
overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 
26:2544-2549, 2008 
77. Han Y, Smith MT. Pathobiology of cancer chemotherapy-induced peripheral neuropathy 
(CIPN). Front Pharmacol  4:156, 2013 
78. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and 
evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol  33:15-49, 2006 
79. Herdon CM. Pharmacologic management of cancer pain. J Neurosci Nurs 35:321-326, 2003 
80. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, 
Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-
Johnston N, Bak K, Loprinzi CL, American Society of Clinical O. Prevention and management 
of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American 
Society of Clinical Oncology clinical practice guideline. J Clin Oncol  32:1941-1967, 2014 
81. Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, Minasian LM, Unger J. 
Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among 
Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol 
34:3014-3022, 2016 
82. Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC. 
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann 
Oncol 24:1472-1478, 2013 
83. Hong JS, Tian J, Wu LH. The influence of chemotherapy-induced neurotoxicity on 
psychological distress and sleep disturbance in cancer patients. Curr Oncol  21:174-180, 2014 
84. Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current Treatment and a 
Collaborative Pathway to Success. J Clin Oncol 33:3029-3035, 2015 
85. Janjan NA, Payne R, Gillis T, Podoloff D, Libshitz HI, Lenzi R, Theriault R, Martin C, Yasko A. 
Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J 
Pain Symptom Manage 16:171-178, 1998 
86. Johanes C, Monoarfa RA, Ismail RI, Umbas R. Anxiety level of early- and late-stage prostate 
cancer patients. Prostate Int  1:177-182, 2013 
87. Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Bone metastasis as the first 
manifestation of lung cancer. Int J Clin Pract 57:184-186, 2003 
88. Kirou-Mauro AM, Hird A, Wong J, Sinclair E, Barnes EA, Tsao M, Danjoux C, Chow E. Has pain 
management in cancer patients with bone metastases improved? A seven-year review at an 
outpatient palliative radiotherapy clinic. J Pain Symptom Manage 37:77-84, 2009 
89. Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, Griffin C, 
Cameron JL, Yeo CJ, Kern S, Hruban RH. Prospective risk of pancreatic cancer in familial 
pancreatic cancer kindreds. Cancer Res 64:2634-2638, 2004 
90. Krech RL, Walsh D. Symptoms of pancreatic cancer. J Pain Symptom Manage 6:360-367, 
1991 
91. Kurosaka S, Satoh T, Chow E, Asano Y, Tabata K, Kimura M, Tsumura H, Matsumoto K, 
Ishiyama H, Inoue Y, Hayakawa K, Baba S. EORTC QLQ-BM22 and QLQ-C30 quality of life 
scores in patients with painful bone metastases of prostate cancer treated with strontium-
89 radionuclide therapy. Ann Nucl Med 26:485-491, 2012 
92. Laird BJ, Walley J, Murray GD, Clausen E, Colvin LA, Fallon MT. Characterization of cancer-
induced bone pain: an exploratory study. Support Care Cancer  19:1393-1401, 2011 
93. Lam DK, Dang D, Flynn AN, Hardt M, Schmidt BL. TMPRSS2, a novel membrane-anchored 
mediator in cancer pain. Pain  156:923-930, 2015 
94. Lam MGEH, De Klerk JMH, Van Rijk PP. 186Re-HEDP for metastatic bone pain in breast 
cancer patients. Eur J Nucl Med Mol Imaging 31:S162-S170, 2004 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
  Chronic Cancer Pain 
 
31 
 
95. Langford DJ, Tripathy D, Paul SM, West C, Dodd MJ, Schumacher K, Miaskowski C. 
Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain. J Pain 
12:495-507, 2011 
96. Lewis MA, Zhao F, Jones D, Loprinzi CL, Brell J, Weiss M, Fisch MJ. Neuropathic Symptoms 
and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or 
Prostate Cancer: Results From a Prospective Multicenter Study. J Pain Symptom Manage  
49:1016-1024, 2015 
97. Li Y, Adamek P, Zhang H, Tatsui CE, Rhines LD, Mrozkova P, Li Q, Kosturakis AK, Cassidy RM, 
Harrison DS, Cata JP, Sapire K, Zhang H, Kennamer-Chapman RM, Jawad AB, Ghetti A, Yan J, 
Palecek J, Dougherty PM. The Cancer Chemotherapeutic Paclitaxel Increases Human and 
Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4. J Neurosci  35:13487-
13500, 2015 
98. Li Y, Zhang H, Kosturakis AK, Cassidy RM, Zhang H, Kennamer-Chapman RM, Jawad AB, 
Colomand CM, Harrison DS, Dougherty PM. MAPK signaling downstream to TLR4 contributes 
to paclitaxel-induced peripheral neuropathy. Brain Behav Immun  49:255-266, 2015 
99. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux 
PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-
analyses of studies that evaluate health care interventions: explanation and elaboration. Ann 
Intern Med  151:W65-94, 2009 
100. Maixner W, Fillingim RB, Williams DA, Smith SB, Slade GD. Overlapping Chronic Pain 
Conditions: Implications for Diagnosis and Classification. J Pain 17:T93-T107, 2016 
101. Malik B, Stillman M. Chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci 
Rep 8:56-65, 2008 
102. Mantyh P. Bone cancer pain: causes, consequences, and therapeutic opportunities. Pain  154 
Suppl 1:S54-62, 2013 
103. Mantyh PW. Bone cancer pain: from mechanism to therapy. Curr Opin Support Palliat Care  
8:83-90, 2014 
104. Massey RL, Kim HK, Abdi S. Brief review: Chemotherapy-induced painful peripheral 
neuropathy (CIPPN): Current status and future directions. Can J Anesth 61:754-762, 2014 
105. McCaffrey G, Thompson ML, Majuta L, Fealk MN, Chartier S, Longo G, Mantyh PW. NGF 
blockade at early times during bone cancer development attenuates bone destruction and 
increases limb use. Cancer Res  74:7014-7023, 2014 
106. Mendoza TR, Koyyalagunta D, Burton AW, Thomas SK, Phan MH, Giralt SA, Shah JJ, Cleeland 
CS. Changes in pain and other symptoms in patients with painful multiple myeloma-related 
vertebral fracture treated with kyphoplasty or vertebroplasty. J Pain  13:564-570, 2012 
107. Mercadante S, Catala E, Arcuri E, Casuccio A. Celiac plexus block for pancreatic cancer pain: 
factors influencing pain, symptoms and quality of life.J Pain Symptom Manage 26:1140-
1147, 2003 
108. Miaskowski C, Cooper BA, Melisko M, Chen LM, Mastick J, West C, Paul SM, Dunn LB, 
Schmidt BL, Hammer M, Cartwright F, Wright F, Langford DJ, Lee K, Aouizerat BE. Disease 
and treatment characteristics do not predict symptom occurrence profiles in oncology 
outpatients receiving chemotherapy. Cancer  120:2371-2378, 2014 
109. Mick G, Baron R, Correa-Illanes G, Hans G, Mayoral V, Frias X, Sintes D, Keller T. Is an easy 
and reliable diagnosis of localized neuropathic pain (LNP) possible in general practice? 
Development of a screening tool based on IASP criteria. Curr Med Res Opin 30:1357-1366, 
2014 
110. Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ, Committee IESS. Carpal tunnel 
syndrome and musculoskeletal symptoms in postmenopausal women with early breast 
cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective 
analysis of the Intergroup Exemestane Study. Lancet Oncol  13:420-432, 2012 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
  Chronic Cancer Pain 
 
32 
 
111. Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. 
Cancer Treat Rev 40:872-882, 2014 
112. Mitera G, Zeiadin N, Kirou-Mauro A, DeAngelis C, Wong J, Sanjeevan T, Sinclair E, Danjoux C, 
Barnes E, Tsao M, Sahgal A, Chow E. Retrospective assessment of cancer pain management 
in an outpatient palliative radiotherapy clinic using the Pain Management Index. J Pain 
Symptom Manage 39:259-267, 2010 
113. Montgomery K, Laird B, Lesley C, Fallon M. A characterization study of breakthrough pain in 
cancer induced bone pain. Palliat Medicine  26 (4):565-566, 2012 
114. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, 
Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van 
de Velde H, Deraedt W, Harousseau JL. Subcutaneous versus intravenous administration of 
bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-
inferiority study. Lancet Oncol 12:431-440, 2011 
115. Mulvey MR, Rolke R, Klepstad P, Caraceni A, Fallon M, Colvin L, Laird B, Bennett MI, SIG ICP, 
the ERN. Confirming neuropathic pain in cancer patients: applying the NeuPSIG grading 
system in clinical practice and clinical research. Pain  155:859-863, 2014 
116. Nahman-Averbuch H, Yarnitsky D, Granovsky Y, Sprecher E, Steiner M, Tzuk-Shina T, Pud D. 
Pronociceptive pain modulation in patients with painful chemotherapy-induced 
polyneuropathy. J Pain Symptom Manage 42:229-238, 2011 
117. Niu L, Wang Y, Yao F, Wei C, Chen Y, Zhang L, Chen J, Li J, Zuo J, Xu K. Alleviating visceral 
cancer pain in patients with pancreatic cancer using cryoablation and celiac plexus block. 
Cryobiology 66:105-111, 2013 
118. Nomiya T, Teruyama K, Wada H, Nemoto K. Time course of pain relief in patients treated 
with radiotherapy for cancer pain: a prospective study.Clin J Pain  26:38-42, 2010 
119. Nudelman KN, McDonald BC, Wang Y, Smith DJ, West JD, O'Neill DP, Zanville NR, Champion 
VL, Schneider BP, Saykin AJ. Cerebral Perfusion and Gray Matter Changes Associated With 
Chemotherapy-Induced Peripheral Neuropathy. J Clin Oncol 34:677-683, 2016 
120. Pachman DR, Watson JC, Lustberg MB, Wagner-Johnston ND, Chan A, Broadfield L, Cheung 
YT, Steer C, Storey DJ, Chandwani KD, Paice J, Jean-Pierre P, Oh J, Kamath J, Fallon M, Strik H, 
Koeppen S, Loprinzi CL. Management options for established chemotherapy-induced 
peripheral neuropathy. Support Care Cancer 22:2281-2295, 2014 
121. Paice JA. Chronic treatment-related pain in cancer survivors. Pain  152:S84-89, 2011 
122. Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan 
MC. Chemotherapy-induced peripheral neurotoxicity: a critical analysis.Ca Cancer J Clin 
63:419-437, 2013 
123. Phillips LL. Managing the pain of bone metastases in the home environment. Am J Hosp 
Palliat Med 15:32-42, 1998 
124. Pignataro RM, Swisher AK. Chemotherapy induced peripheral neuropathy: risk factors, 
pathophysiology, assessment, and potential physical therapy interventions. Rehabil Oncol  
28:10-18, 2010 
125. Pollen JJ, Schmidt JD. Bone pain in metastatic cancer of prostate. Urology 13:129-134, 1979 
126. Portenoy RK. Treatment of cancer pain. Lancet. 377:2236-2247, 2011 
127. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain  
41:273-281, 1990 
128. Reddy SM, Vergo MT, Paice JA, Kwon N, Helenowski IB, Benson AB, Mulcahy MF, Nimeiri HS, 
Harden RN. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion 
Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy 
in Gastrointestinal Malignancies. Clin Colorectal Cancer  15:37-46, 2016 
129. Reyes-Gibby CC, Anderson KO, Merriman KW, Todd KH, Shete SS, Hanna EY. Survival 
patterns in squamous cell carcinoma of the head and neck: pain as an independent 
prognostic factor for survival. J Pain 15:1015-1022, 2014 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
  Chronic Cancer Pain 
 
33 
 
130. Riccio AI, Wodajo FM, Malawer M. Metastatic carcinoma of the long bones. Am Fam 
Physician  76:1489-1494, 2007 
131. Richardson PG, Laubach JP, Schlossman RL, Mitsiades C, Anderson K. Complications of 
multiple myeloma therapy, part 1: Risk reduction and management of peripheral 
neuropathy and asthenia. J Natl Compr Canc Netw 8:S4-S12, 2010 
132. Rizzoli R, Body JJ, Brandi ML, Cannata-Andia J, Chappard D, El Maghraoui A, Gluer CC, 
Kendler D, Napoli N, Papaioannou A, Pierroz DD, Rahme M, Van Poznak CH, De Villiers TJ, El 
Hajj Fuleihan G. Cancer-associated bone disease. Osteoporos Int 24:2929-2953, 2013 
133. Rodionov V, Bogomolova O, Rodionova M. Clinical symptoms of bone marrow metastases in 
breast cancer patients. Breast 20:S41, 2011 
134. Rustoen T, Moum T, Padilla G, Paul S, Miaskowski C. Predictors of quality of life in oncology 
outpatients with pain from bone metastasis. J Pain Symptom Manage 30:234-242, 2005 
135. Rykowski JJ, Hilgier M: Efficacy of neurolytic celiac plexus block in varying locations of 
pancreatic cancer: influence on pain relief. Anesthesiology  92:347-354, 2000 
136. Ryo H, Sakai H, Yoneda S, Noguchi Y. Bone metastasis of primary lung cancer. Nihon Kokyuki 
Gakkai zasshi = the journal of the Japanese Respiratory Society. 36:317-322, 1998 
137. Sansur CA, Pouratian N, Dumont AS, Schiff D, Shaffrey CI, Shaffrey ME. Part II: spinal-cord 
neoplasms--primary tumours of the bony spine and adjacent soft tissues. Lancet Oncol  
8:137-147, 2007 
138. Schmidt BL. The neurobiology of cancer pain. J Oral Maxillofac Surg  73:S132-135, 2015 
139. Schmidt BL. What pain tells us about cancer. Pain  156 Suppl 1:S32-34, 2015 
140. Scott AC, McConnell S, Laird B, Colvin L, Fallon M. Quantitative Sensory Testing to assess the 
sensory characteristics of cancer-induced bone pain after radiotherapy and potential clinical 
biomarkers of response. Eur J Pain 16:123-133, 2012 
141. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. 
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A 
systematic review and meta-analysis. Pain  155:2461-2470, 2014 
142. Sestak I, Sapunar F, Cuzick J. Aromatase inhibitor-induced carpal tunnel syndrome: results 
from the ATAC trial. J Clin Oncol  27:4961-4965, 2009 
143. Sharma M, Simpson KH, Bennett MI, Gupta S: Practical Management of Complext Cancer 
Pain, Oxford University Press, Oxford, 2014. 
144. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. Ca Cancer J Clin 66:7-30, 2016 
145. Silverman DT, Schiffman M, Everhart J, Goldstein A, Lillemoe KD, Swanson GM, Schwartz AG, 
Brown LM, Greenberg RS, Schoenberg JB, Pottern LM, Hoover RN, Fraumeni JF, Jr. Diabetes 
mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic 
cancer. Br J Cancer  80:1830-1837, 1999 
146. Slosky LM, Largent-Milnes TM, Vanderah TW. Use of animal models in understanding 
cancer-induced bone pain. Cancer Growth Metastasis 8:47-62, 2015 
147. Stubblefield MD, McNeely ML, Alfano CM, Mayer DK. A prospective surveillance model for 
physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral 
neuropathy. Cancer  118:2250-2260, 2012 
148. Taverner T. Neuropathic pain in people with cancer (part 1): incidence, manifestation, and 
assessment. Int J Palliat Nurs 20:442-447, 2014 
149. Tersmette AC, Petersen GM, Offerhaus GJ, Falatko FC, Brune KA, Goggins M, Rozenblum E, 
Wilentz RE, Yeo CJ, Cameron JL, Kern SE, Hruban RH. Increased risk of incident pancreatic 
cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer 
Res  7:738-744, 2001 
150. Themistocleous AC. The pain in neuropathy study (PiNS): a cross-sectional observational 
study determining the somatosensory phenotype of painful and painless diabetic 
neuropathy. Pain 157: 1132-45, 2016 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
  Chronic Cancer Pain 
 
34 
 
151. Tofthagen C, Visovsky CM, Hopgood R. Chemotherapy-Induced Peripheral Neuropathy. Clin J 
Oncol Nurs 17:138-144, 2013 
152. Toyama S, Shimoyama N, Ishida Y, Koyasu T, Szeto HH, Shimoyama M. Characterization of 
Acute and Chronic Neuropathies Induced by Oxaliplatin in Mice and Differential Effects of a 
Novel Mitochondria-targeted Antioxidant on the Neuropathies. Anesthesiology  120:459-
473, 2014 
153. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, 
First MB, Giamberardino MA, Kaasa S, Kosek E, Lavand'homme P, Nicholas M, Perrot S, 
Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JW, Wang SJ. A classification of chronic pain 
for ICD-11. Pain  156:1003-1007, 2015 
154. Trinkaus M, Simmons C, Myers J, Dranatisaris G, Clemons M. Skeletal-related events (SREs) 
in breast cancer patients with bone metastases treated in the nontrial setting. Support Care 
Cancer 18:197-203, 2010 
155. Turk DC, Fillingim RB, Ohrbach R, Patel KV. Assessment of Psychosocial and Functional 
Impact of Chronic Pain. J Pain  17:T21-49, 2016 
156. Vardeh D, Mannion RJ, Woolf CJ. Towards a mechanism based pain diagnosis. J Pain 17:T50-
69, 2016 
157. Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB. Chemotherapy-induced pain and 
neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. 
Pain  157:560-568, 2016 
158. Vichaya EG, Wang XS, Boyette-Davis JA, Mendoza TR, He Z, Thomas SK, Shah N, Williams LA, 
Cleeland CS, Dougherty PM. Subclinical pretreatment sensory deficits appear to predict the 
development of pain and numbness in patients with multiple myeloma undergoing 
chemotherapy. Cancer Chemother Pharmacol 71:1531-1540, 2013 
159. Wilson KG, Chochinov HM, Allard P, Chary S, Gagnon PR, Macmillan K, De Luca M, O'Shea F, 
Kuhl D, Fainsinger RL. Prevalence and correlates of pain in the Canadian National Palliative 
Care Survey. Pain Res Manag  14:365-370, 2009 
160. Wong K, Zeng L, Zhang L, Bedard G, Wong E, Tsao M, Barnes E, Danjoux C, Sahgal A, Holden 
L, Lauzon N, Chow E. Minimal clinically important differences in the brief pain inventory in 
patients with bone metastases. Support Care Cancer 21:1893-1899, 2013 
161. Yang Y, Zhang YG, Lin GA, Xie HQ, Pan HT, Huang BQ, Liu JD, Liu H, Zhang N, Li L, Chen JH. 
Spinal changes of a newly isolated neuropeptide endomorphin-2 concomitant with 
vincristine-induced allodynia. PLoS One  9:e89583, 2014 
162. Zedan AH, Vilholm OJ. Chemotherapy-induced polyneuropathy: Major agents and 
assessment by questionnaires. Basic Clin Pharmacol Toxicol  115:193-200, 2014 
 
  
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
  Chronic Cancer Pain 
 
35 
 
Legend 
 
Figure 1. PRISMA diagram 
 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) is an 
evidence-based minimum set of items for reporting systematic reviews  
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Table 1. Dimension 1: Core Diagnostic Criteria for CIBP 
1. History of primary or metastatic bone cancer diagnosed by imaging and physical 
examination 
2. Presence of continuous, background pain (usually described as annoying, dull, gnawing, 
aching, and/or nagging) in one or more locations generally consistent with  known 
distribution of bone lesions
40, 41, 43, 49, 50, 61, 92, 133
 
3. Presence of evoked or spontaneous pain (often described as electric or shock-like) in 
one or more locations generally consistent with  known distribution of bone lesions, 
associated with weight bearing or movement or can occur spontaneously
40, 41, 43, 48-50, 61, 
85, 92, 133
  
4. Clinical examination over the site of pain reveals:  
- Hyperalgesia to blunt,non-noxious pressure or pin-prick stimuli or 
- Hypoesthesia to non-noxious thermal stimuli or 
- Hypoesthesia to light touch stimuli
140
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Table 2. Dimension 1: Core Diagnostic Criteria for CIPN 
1. Onset of pain following exposure to a chemotherapeutic agent known to be neurotoxic 
2. Presence of painful symptoms in a symmetrical stocking and glove distribution 
beginning in lower extremities which may progress to the upper extremities, although 
finding in the feet and not in the hands are common 
3. Painful symptoms are accompanied by non-painful symptoms (e.g., “pins and needles” 
or numbness) in a similar distribution. 
4. Clinical examination reveals sensory loss to one or more sensory modalities and/or 
evoked pain in a stocking and glove distribution, as reflected in at least one of the 
following:  
– Hypoesthesia – bilateral increase in detection thresholds to tactile, vibration, or 
non-noxious warm or cool stimuli or  
– Hypoalgesia – bilateral increase in pain detection thresholds to blunt pressure or 
pinprick stimuli, or 
– Hyperalgesia – bilateral decrease in pain detection threshold to noxious heat or 
cold stimuli 
5. Magnitude of the sensory abnormalities is disproportionately greater than the 
magnitude of any motor abnormalities in the affected region (except in the case of 
neuropathy after vinca alkaloids) 
6. No other condition (e.g., polyneuropathy of other origin) could plausibly account for 
painful symptoms 
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Table 3. Dimension 1: Core Diagnostic Criteria for PCP 
 
1. History of pancreatic cancer diagnosed by imaging, physical examination, and in some 
cases biopsy and laboratory analysis of blood or tissues for tumor markers 
2. Presence of pain in upper abdominal region (typically referred to the epigastric region or 
upper abdominal quadrants) spreading posteriorly and/or radiating to the back 
3. On clinical examination, the patient displays tenderness on upper abdominal palpation 
4. No other condition (e.g., constipation) could plausibly account for persisting pain in the 
upper abdomen 
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Figure 1. PRISMA diagram 
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AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions 
Highlights 
• No comprehensive, universally accepted cancer pain classification system currently 
exists.  
• An evidence-based taxonomy would enhance cancer pain research efforts by providing  
consistent diagnostic criteria, ensuring comparability across clinical trials.  
• As part of a collaborative effort between the Analgesic, Anesthetic, and Addiction 
Clinical Trial Translations Innovations Opportunities and Networks (ACTTION) and the 
American Pain Society (APS), the ACTTION-APS Pain Taxonomy (AAPT) initiative worked 
to develop the characteristics of an optimal diagnostic system for cancer pain.   
• Diagnostic criteria were developed for three chronic pain syndromes associated with 
cancer (i.e., bone pain and pancreatic cancer pain as models of pain related to a tumor) 
or its treatment (i.e., chemotherapy-induced peripheral neuropathy). Future efforts will 
subject these diagnostic categories and criteria to systematic empirical evaluation of 
their feasibility, reliability and validity and extension to other cancer-related pain 
syndromes.   
 
